Genflow Biosciences plc (LON:GENF) has announced progress across its two principal SIRT6 patent families covering its centenarian-derived SIRT6 variant (SIRT6c; N308K/A313S).
· US patent application covering the use of SIRT6c in NAFLD and NASH published
· Track One prioritised examination granted for the foundational in-licensed US SIRT6 compound of matter patent application
· Corresponding European application at an advanced stage of examination
Dr Eric Leire, Chief Executive Officer of Genflow Biosciences, commented: “Protecting our centenarian-derived SIRT6 variant remains central to Genflow’s strategy. Our foundational SIRT6c family, which is exclusively licensed to Genflow, seeks broad protection for the variant, while our Company-owned MASH family adds indication-specific claims. Progress in the US and Europe, alongside our delivery and muscular-disease filings, advances a layered intellectual property strategy spanning the variant, its delivery and its potential therapeutic applications.”
US NAFLD PATENT APPLICATION PUBLISHED
The company has been informed that the United States Patent and Trademark Office (“USPTO”) has published Genflow’s patent application US 2026/0199524 A1, entitled “Variants of Sirtuin 6 for the Treatment of Non-Alcoholic Fatty Liver Disease”.
The application relates to the use of the Company’s centenarian-derived SIRT6 variant (N308K/A313S) in the prevention and/or treatment of non-alcoholic fatty liver disease (“NAFLD”), including non-alcoholic steatohepatitis (“NASH”).
The application names Dr. Manlio Vinciguerra and Dr. Eric Leire as inventors and is assigned to Genflow Biosciences Plc.
Publication is a procedural step in the examination process and does not constitute the grant of a patent.
PRIORITISED EXAMINATION GRANTED FOR FOUNDATIONAL US APPLICATION
The USPTO has granted Track One prioritised examination for the foundational in-licensed US SIRT6 patent application, “Variants of SIRT6 for Use in Preventing and/or Treating Age-Related Diseases”.
The application forms part of a patent family jointly owned by the University of Rochester, The Trustees of Columbia University in the City of New York and Albert Einstein College of Medicine and exclusively licensed worldwide to Genflow.
Track One status accelerates examination but does not guarantee grant or determine the final scope of any claims that may be allowed.
The foundational patent family is also progressing in other jurisdictions, including Canada, where a request for examination has been filed for application (CA 3218849).
EUROPEAN APPLICATION AT AN ADVANCED STAGE
The corresponding European application (IBIO-1826/EP) is at last stage before the European Patent Office (“EPO”). The company is currently awaiting a communication under Rule 71(3) EPC. The timing of grant remains subject to completion of the EPO’s formal procedures. Further updates will be provided as appropriate.
